Document:

Exhibit

November 19, 2016

Langley Holdings plc.
Enterprise Way, Retford
Nottinghamshire, DN22 7HH, United Kingdom
Attn:    Bernard A. Watson, Group Commercial Director

Piller USA, Inc.
45 Wes Warren Drive
Middletown, New York 10941-2047
Attn: A.C. Dyke, Chairman

		
	Re:
	Asset Purchase Agreement dated September 29, 2016 

Dear Bernard:
    
We refer you to that certain Asset Purchase Agreement (the “Asset Purchase Agreement”) dated September 29, 2016 by and among Active Power, Inc., a Delaware corporation (the “Seller”), Piller USA, Inc., a Delaware corporation (the “Buyer”) and Langley Holdings plc, a United Kingdom public limited company (the “Parent”). Capitalized terms used herein but not otherwise defined in this letter agreement shall have the meanings given thereto in the Asset Purchase Agreement. In connection with the closing of the transactions contemplated by the Asset Purchase Agreement, the Seller, the Buyer and the Parent hereby agree that the following shall apply:

1.Addition of Buyer Parties and Purchase of Certain Equity Interests. Piller Group GmbH, Piller Germany Gmbh & Co. Kg. and Piller UK Ltd. shall each hereby be considered a “Buyer” under the Asset Purchase Agreement. Piller Group GmbH shall purchase the shares of Active Power (Hong Kong) Limited. Piller Germany Gmbh & Co. Kg. shall purchase the shares of Active Power (Switzerland) AG. Piller UK Ltd. shall purchase the shares of Active Power Solutions Ltd.
2.Waiver of Consent to Assign.  Pursuant to 4.2 of the Asset Purchase Agreement, prior to the Closing, the Seller is required to obtain all third party consents that are required to effectively transfer the Acquired Assets to the Buyer. The Buyer hereby waives the requirement that the counterparties to the agreements listed on Exhibit A attached hereto consent to the assignment such agreements. 
3.Waiver of Requirement to Enter into a Sublease. Pursuant to Section 4.8 of the Asset Purchase Agreement, at the Closing, the Buyer and the Seller shall enter into a sublease for the Headquarters Facility. The Parties hereby waive the requirement that the Buyer and the Seller enter into a sublease for the Headquarters Facility prior to the Closing. The Parties hereby agree to 

Execution Version

use their commercially reasonable efforts to reach a mutually agreeable solution to the issue of the Buyer’s access to the premises located at the Headquarters Facility within thirty (30) days of the Closing. The Buyer hereby agrees to remit to the Seller all rent and building and facilities expenses associated with the premises located at the Headquarters Facility for each month the Buyer has access to the Headquarters Facility. 
4.Purchase of Certain Intercompany Loans.  The intercompany loan receivables held by the Seller associated with the following subsidiaries shall be purchased by Parent instead of Buyer: (i) Active Power Solutions Ltd. in the amount of $2,651,892 as of October 31, 2016, (ii) Active Power (Germany) GmbH in the amount of $3,368,712 as of October 31, 2016 and (iii) Active Power (Beijing) Co. Ltd. in the amount of $2,184,261 as of October 31, 2016. 
5.Retained Assets and Retained Liabilities. The following items listed on Exhibit B attached hereto shall be included in the definition of Retained Assets and the following items listed on Exhibit C attached hereto shall be included in the definition of Retained Liabilities. 
6.Threatened Claim. Pursuant to Section 5.1(ii) of the Asset Purchase Agreement, the Buyer is not obligated to consummate the transactions to be performed by it in connection with the Closing unless the representations and warranties set forth in part 2 of the Asset Purchase Agreement are true and correct as of the Closing Date. Section 2.17 of the Asset Purchase Agreement states that there are no claims, actions, suits, demands or other proceedings pending or, to the Sellers’ Knowledge, threatened against the Seller or affecting the Seller or any of its property. Buyer and Parent hereby acknowledge the presence of the threatened claim as more fully described on Exhibit D attached hereto (the “Claim”) and, with respect to the Claim, hereby waive the requirement of Section 5.1(ii) of the Asset Purchase Agreement. 
7.Further Assurances.  The Seller agrees to execute and deliver any further instruments and take such other action as Buyer or Parent may reasonably request with respect to the transactions contemplated by this letter agreement.
8.Miscellaneous.  Except as amended by the provisions of this letter agreement, the terms and provisions contained in the Asset Purchase Agreement shall continue to govern the rights and obligations of the parties, and all provisions and covenants in the Asset Purchase Agreement shall remain in full force and effect as stated therein. This letter agreement and the Asset Purchase Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter thereof and hereof. 
9.Counterparts.  This letter agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Delivery of the executed signature pages by facsimile transmission or in “portable document format” shall constitute effective and binding execution and delivery of this letter agreement. 

Execution Version

Signature page follows.

Execution Version

Please acknowledge that this letter agreement accurately reflects the agreement between the parties hereto regarding the matters set forth above by executing this letter agreement in the space provided below.
Sincerely,
ACTIVE POWER, INC.

By:      /s/ Mark A. Ascolese
Mark A. Ascolese, CEO

Accepted and agreed as of the date
first set forth above:

PILLER USA, INC.

By:      /s/ A.C. Dyke
Name:     A.C. Dyke
Title:     Chairman

LANGLEY HOLDINGS PLC

By:     /s/ Bernard Langley
Name:      Bernard Langley
Title:     Director

Signature Page to
Letter AgreementExhibit 10.20

 

CREATIVE MEDICAL HEALTH,
INC.

2007 W Peoria Ave Phoenix,
Arizona 85029

 

 

November 11, 2016

 

 

Dr. Amit Patel

l040 Chartwell Ct.

Salt Lake City, UT 84121

 

		Re:	Scientific Advisory Board Dear Amit,

 

This letter will confirm the agreement between
you and Creative Medical Health, Inc. (the “Company”) to continue service as a consultant to the Company and its
subsidiaries or affiliates and as a member of the Company’s Scientific Advisory Board (the “Advisory Board”), and
will memorialize the terms originally agreed between us by written agreement entered into in approximately October 2011.
After diligent search, neither you nor the Company has located a copy of the original agreement and the purpose of this
letter is to set forth the terms and conditions of the original agreement. Therefore,
the following term and conditions are agreed to by you and the Company and are effective retroactively, as applicable, to the
commencement of services on the Advisory Board under the original agreement.

 

When
requested by the CEO of the Company or Creative Medical Technology Holdings, Inc. (“CMTH”), you will provide
your professional observations, questions, advice and recommendations, as appropriate, regarding any inquiry from the Company
or CMTH involving your areas of professional expertise, so long as such inquiries are reasonable in frequency and timing, as
determined by you at your reasonable discretion. You also agree that the Company and CMTH are authorized to publish your name
and your engagement as a consultant to the Company and CMTH, and as a member of the Advisory Board, demonstrating
the professional association between you and the Company and CMTH, but only in the manner and media previously approved by
you, which approval shall not be unreasonably withheld. You acknowledge and agree, however, that your name and consultancy
with the Company and CMTH and your current employment-related directorships and
positions may be accurately disclosed by the Company and CMTH within private offering memoranda and public filings with the
federal and state governments, as permitted or required by applicable law.

 

In
exchange for both the provision of your consulting services to the Company and CMTH, your service on the Advisory Board, and your
agreement to associating with the Company .and CMTH through publication of your name, employment and professional achievements
in connection with any Company or CMTH publications, you will be paid $5,000 per month.

 

Excluding
published or publicly available information, you acknowledge that in performing as a trusted consultant of Company and CMTH, or
as a member of the Advisory Board, you may gain access to non-public information, directly or indirectly, about Company or CMTH,
including, without limitation, their products, processes, inventions, experimental developments, formulae, testing methods, customer
and supplier identification, product cost or profit information, financial information, and matters which although technically
not trade secrets, the dissemination to or knowledge of others might prove prejudicial to the Company or CMTH, and any information
received from third parties for which the Company or CMTH has responsibility to keep confidential (hereinafter referred to as “Confidential
Information”). You agree that at all times during and after your consultancy, you will (i)
bold in confidence and refrain from disclosing to any other party any Confidential Information, whether written or oral, tangible
or intangible;

 

     

     

    

Dr. Amit Patel

November 11, 2016

Page 2

 

 

(ii)
use the Confidential Information solely in connection with your consultancy with the Company and CMTH, or membership on the Advisory
Board, and for no other purpose; (iii) take all precautions necessary to ensure that the Confidential
Information is not, and will not be permitted to be, shown, copied or disclosed to third parties, without the prior written consent
of the Company or CMTH, as applicable; and (iv) observe all security policies
implemented by the Company and CMTH from time to time with respect to the Confidential
Information. In the event that you are ordered to disclose any Confidential Information, whether
in a legal or regulatory proceeding or otherwise, you agree to provide the Company or CMTH,
as applicable, with prompt notice of such request or order so that the Company or CMTH may seek to prevent disclosure. In the case
of any disclosure, you agree to disclose only that portion of the Confidential Information that you are ordered to disclose.

 

Your
services as a consultant and member of the Advisory Board are terminable by the Company at any time, with or without cause, and
likewise you may resign at any time. Termination or resignation shall be effected by written notice to the other party.

 

Please
confirm your agreement to the terms and conditions set forth above by executing and returning to the Company a copy of this letter.
When executed by both parties, this letter agreement constitutes the entire understanding between us with
respect to the subject matter hereof and supersedes all negotiations, representations, prior
discussions, and agreements between us relating to the subject matter of this letter agreement.

 

	Regards, 
	 
	 
	/s/ Timothy Warbington
	Timothy Warbington, CEO

 

The
foregoing terms and conditions are agreed to by the undersigned.

 

	 	 
	Date: November 15, 2016	/s/
    Amit Patel
	 	Dr. Amit Patel

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]